AU2000272858A1 - Pharmaceutical composition for treating hyperhomocysteinaemia caused by medicaments - Google Patents

Pharmaceutical composition for treating hyperhomocysteinaemia caused by medicaments

Info

Publication number
AU2000272858A1
AU2000272858A1 AU2000272858A AU7285800A AU2000272858A1 AU 2000272858 A1 AU2000272858 A1 AU 2000272858A1 AU 2000272858 A AU2000272858 A AU 2000272858A AU 7285800 A AU7285800 A AU 7285800A AU 2000272858 A1 AU2000272858 A1 AU 2000272858A1
Authority
AU
Australia
Prior art keywords
hyperhomocysteinaemia
medicaments
treating
caused
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2000272858A
Inventor
Jutta Dierkes
Klaus Luley
Sabine Westphal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2000272858A1 publication Critical patent/AU2000272858A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • A61K31/714Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
AU2000272858A 2000-02-03 2000-09-08 Pharmaceutical composition for treating hyperhomocysteinaemia caused by medicaments Abandoned AU2000272858A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10004651A DE10004651A1 (en) 2000-02-03 2000-02-03 Combination of antihypertensive agents with drugs that reduce homocysteine levels
DE10004651 2000-02-03
PCT/EP2000/008801 WO2001056609A1 (en) 2000-02-03 2000-09-08 Pharmaceutical composition for treating hyperhomocysteinaemia caused by medicaments

Publications (1)

Publication Number Publication Date
AU2000272858A1 true AU2000272858A1 (en) 2001-08-14

Family

ID=7629642

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2000272858A Abandoned AU2000272858A1 (en) 2000-02-03 2000-09-08 Pharmaceutical composition for treating hyperhomocysteinaemia caused by medicaments

Country Status (3)

Country Link
AU (1) AU2000272858A1 (en)
DE (1) DE10004651A1 (en)
WO (1) WO2001056609A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
WO2003045359A2 (en) * 2001-11-26 2003-06-05 Astion Oncology Aps Combination of cimetidine and cysteine derivatives for treating cancer
BE1015608A6 (en) 2003-07-15 2005-06-07 Messadek Jallal TREATMENT arteritis.
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
EP1663174A1 (en) * 2003-08-05 2006-06-07 Galephar M/F Single unit pharmaceutical composition comprising a mixture of a fibrate and a homocysteine reducing agent
IL157397A (en) * 2003-08-14 2013-03-24 Dpharm Ltd Compounds, pharmaceutical compositions comprising same and uses thereof for the preparation of a medicament for the treatment of epilepsy
ITRM20030442A1 (en) * 2003-09-26 2005-03-27 Medosan Ind Biochimiche Riuni Te S R L PHARMACEUTICAL COMPOSITION (STRESSEN) FOR THE TREATMENT OF HYPEROMOCISTEINEMIA.
EP1768675A4 (en) * 2004-07-09 2008-03-12 Medicure Int Inc Combination therapies employing nicotinic acid derivatives or fibric acid derivatives
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
EP1681055A1 (en) * 2005-01-13 2006-07-19 PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG Pharmaceutical preparation for the treatment of elevated homocysteine level
WO2006086856A1 (en) * 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
MX2007013486A (en) 2005-04-27 2008-03-14 Jallal Messadek Insulins combinations.
CN100497337C (en) * 2006-11-20 2009-06-10 淮北辉克药业有限公司 Folacin dimethylbiguanide and process for production thereof
CN103386130A (en) * 2013-06-27 2013-11-13 深圳奥萨医药有限公司 ACE inhibitor/thiazide diuretic/5-methyltetrahydrofolate pharmaceutical composition and applications
US10016379B2 (en) 2015-10-30 2018-07-10 Robin L. Webb Method of treatment for third spacing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008221A (en) * 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
AU2899099A (en) * 1998-03-06 1999-09-20 Charles L Brown Composition for treatment and prevention of coronary artery disease

Also Published As

Publication number Publication date
DE10004651A1 (en) 2001-08-16
WO2001056609A1 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
AU2002222118A1 (en) Pharmaceutical compositions for inhalation
AU781269C (en) Pharmaceutical compositions
AU2001250420A1 (en) Pharmaceutical compositions
AU2001274307A1 (en) Pharmaceutical compositions
AU2001271037A1 (en) Pharmaceutical compositions containing dds compounds
AU2001266338A1 (en) Pharmaceutical compositions for angiogenic therapy
AU2002302147A1 (en) Pharmaceutical composition
AU2000272858A1 (en) Pharmaceutical composition for treating hyperhomocysteinaemia caused by medicaments
AU2001290239A1 (en) Medicinal composition
AU2002221115A1 (en) Medicinal compositions having improved absorbability
HUP0401612A3 (en) Pharmaceutical composition suitable for treating diabetes
HUP0100489A3 (en) New piperidine-4-sulphonamide compounds, process for their preparation and pharmaceutical compositions containing them
AU2001273919A1 (en) Pharmaceutical compositions
AU2002215114A1 (en) Pharmaceutical compositions for inhalation
AU3945501A (en) Apparatus for dosage of medicaments
AU2002306687A1 (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
AU4085201A (en) Pharmaceutical composition
AU2001292578A1 (en) Pharmaceutical compounds
AU2882699A (en) Stabilizing composition for pharmaceutical dosage forms
AU2001278705A1 (en) Pharmaceutical composition
AU3586401A (en) Pharmaceutical composition
AU2002331279A1 (en) Pharmaceutical composition for treating hypercholesterolaemia
AU4698900A (en) Pharmaceutical compositions for treating malaria
HU9902296D0 (en) Pharmaceutical composition for treating caltification
AUPR529701A0 (en) Pharmaceutical composition